
GMAB Stock Forecast & Price Target
GMAB Analyst Ratings
Bulls say
Genmab's financial outlook is bolstered by the strong performance of its leading product, DARZALEX, which reported worldwide net sales exceeding previous estimates, suggesting robust market demand and growth potential. The company ended the third quarter of 2025 with approximately $3.4 billion in cash and marketable securities, reflecting a solid balance sheet that supports its ongoing investment in a diverse pipeline of oncology therapies. With upcoming clinical data catalysts and a strong positioning in the multiple myeloma market, Genmab is well-equipped to navigate the challenges in the biotech sector and maintain its profitability.
Bears say
Genmab faces significant financial risks stemming from the slowing sales of its leading product, Darzalex, along with potential setbacks in expanding its label and negative trial outcomes for other key products, particularly Epcoritamab. In a recent trial, Epcoritamab failed to meet primary endpoint efficacy criteria, prompting a reduction in projected approval probabilities, which could adversely affect future revenue streams. Additionally, the company is exposed to macroeconomic factors and dilution risks that may further impact its financial stability and market position.
This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.
GMAB Analyst Forecast & Price Prediction
Start investing in GMAB
Order type
Buy in
Order amount
Est. shares
0 shares